Biotest AG Sees 6% Sales Increase in 2024

Biotest AG reported a 6% rise in sales for the financial year 2024, reaching €726.2 million, up from €684.6 million the previous year. This growth is driven by increased sales of Intratect® and the new Yimmugo®, which saw sales jump by €34.9 million. However, EBIT decreased to €94.5 million due to reduced earnings from technology disclosure and development services for Grifols, S.A.

Yimmugo® was approved by the FDA in June 2024, and Biotest began production for the US market. The company completed the AdFirst Phase III trial and submitted a marketing authorization for Fibrinogen. Despite these developments, Biotest anticipates a mid-single-digit percentage decline in sales for 2025.

Looking ahead, Biotest expects an EBIT of €-55 million to €-75 million in 2025, with ROCE forecasted between –3% to –7%. Operating cash flow is expected to be negatively impacted.